News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
396,857 Results
Type
Article (31948)
Company Profile (58)
Press Release (364851)
Section
Business (112794)
Career Advice (1322)
Deals (24046)
Drug Delivery (93)
Drug Development (59709)
Employer Resources (104)
FDA (9933)
Job Trends (9083)
News (211501)
Policy (25509)
Tag
2024 BioCapital Digital (1)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (4)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (1)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Standard (1)
2026 Pharm Country Premier (1)
Academia (1837)
Accelerated approval (3)
Adcomms (20)
Allergies (65)
Alliances (42254)
ALS (58)
Alzheimer's disease (1093)
Antibody-drug conjugate (ADC) (89)
Approvals (9936)
Artificial intelligence (149)
Autoimmune disease (15)
Automation (6)
Bankruptcy (236)
Best Places to Work (7694)
BIOSECURE Act (15)
Biosimilars (79)
Biotechnology (42)
Bladder cancer (45)
Brain cancer (26)
Breast cancer (174)
Cancer (1500)
Cardiovascular disease (121)
Career advice (1111)
Career pathing (19)
CAR-T (102)
Cell therapy (286)
Cervical cancer (16)
Clinical research (48113)
Collaboration (643)
Compensation (379)
Complete response letters (19)
COVID-19 (2474)
CRISPR (29)
C-suite (104)
Cystic fibrosis (56)
Data (1428)
Decentralized trials (1)
Denatured (9)
Depression (35)
Diabetes (203)
Diagnostics (3553)
Digital health (10)
Diversity (4)
Diversity, equity & inclusion (33)
Drug discovery (82)
Drug pricing (95)
Drug shortages (28)
Duchenne muscular dystrophy (77)
Earnings (40274)
Editorial (32)
Employer branding (13)
Employer resources (94)
Events (45618)
Executive appointments (293)
FDA (10724)
Featured Employer (18)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (446)
Gene editing (71)
Generative AI (12)
Gene therapy (221)
GLP-1 (672)
Government (4071)
Grass and pollen (4)
Guidances (34)
Healthcare (11416)
Huntington's disease (18)
IgA nephropathy (20)
Immunology and inflammation (78)
Indications (21)
Infectious disease (2605)
Inflammatory bowel disease (76)
Inflation Reduction Act (7)
Influenza (49)
Intellectual property (67)
Interviews (231)
IPO (10434)
IRA (40)
Job creations (1748)
Job search strategy (956)
Kidney cancer (7)
Labor market (15)
Layoffs (273)
Leadership (7)
Legal (7051)
Liver cancer (49)
Lung cancer (218)
Lymphoma (101)
Machine learning (4)
Management (32)
Manufacturing (204)
MASH (51)
Medical device (5914)
Medtech (5915)
Mergers & acquisitions (13982)
Metabolic disorders (559)
Multiple sclerosis (51)
NASH (20)
Neurodegenerative disease (66)
Neuropsychiatric disorders (22)
Neuroscience (1458)
NextGen: Class of 2025 (3660)
Non-profit (2769)
Northern California (1541)
Now hiring (4)
Obesity (320)
Opinion (190)
Ovarian cancer (52)
Pain (47)
Pancreatic cancer (63)
Parkinson's disease (105)
Partnered (12)
Patents (145)
Patient recruitment (56)
Peanut (38)
People (24808)
Pharmaceutical (18)
Pharmacy benefit managers (10)
Phase I (14539)
Phase II (20902)
Phase III (16953)
Pipeline (834)
Podcasts (38)
Policy (105)
Postmarket research (1846)
Preclinical (6015)
Press Release (28)
Prostate cancer (73)
Psychedelics (28)
Radiopharmaceuticals (204)
Rare diseases (257)
Real estate (2579)
Recruiting (44)
Regulatory (16080)
Reports (22)
Research institute (1591)
Resumes & cover letters (195)
Rett syndrome (3)
RNA editing (3)
RSV (44)
Schizophrenia (59)
Series A (73)
Series B (38)
Service/supplier (4)
Sickle cell disease (38)
Southern California (1263)
Special edition (5)
Spinal muscular atrophy (137)
Sponsored (18)
Startups (1885)
State (1)
Stomach cancer (11)
Supply chain (47)
Tariffs (9)
The Weekly (28)
United States (12580)
Vaccines (688)
Venture capitalists (24)
Webinars (5)
Weight loss (240)
Women's health (13)
Worklife (10)
Date
Today (71)
Last 7 days (495)
Last 30 days (1822)
Last 365 days (21458)
2025 (5332)
2024 (22354)
2023 (25259)
2022 (33382)
2021 (35891)
2020 (34078)
2019 (27909)
2018 (21242)
2017 (20203)
2016 (18693)
2015 (21495)
2014 (15949)
2013 (12876)
2012 (13625)
2011 (14408)
2010 (13081)
Location
Africa (570)
Alabama (29)
Alaska (3)
Arizona (87)
Arkansas (5)
Asia (25875)
Australia (4667)
California (3355)
Canada (1143)
China (339)
Colorado (145)
Connecticut (150)
Delaware (92)
Europe (62006)
Florida (508)
Georgia (123)
Hawaii (1)
Idaho (28)
Illinois (276)
India (21)
Indiana (181)
Iowa (6)
Japan (110)
Kansas (59)
Kentucky (15)
Louisiana (8)
Maine (28)
Maryland (620)
Massachusetts (2421)
Michigan (99)
Minnesota (131)
Mississippi (1)
Missouri (48)
Montana (20)
Nebraska (10)
Nevada (34)
New Hampshire (20)
New Jersey (1070)
New Mexico (15)
New York (1021)
North Carolina (488)
North Dakota (4)
Northern California (1541)
Ohio (109)
Oklahoma (6)
Oregon (10)
Pennsylvania (744)
Puerto Rico (4)
Rhode Island (12)
South America (795)
South Carolina (10)
South Dakota (1)
Southern California (1263)
Tennessee (52)
Texas (425)
Utah (75)
Virginia (85)
Washington D.C. (35)
Washington State (286)
West Virginia (2)
Wisconsin (27)
396,857 Results for "biotest ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Kedrion Selected by Biotest to Distribute its Immunoglobulin Yimmugo® in the U.S. Following Recent FDA Approval
Kedrion Biopharma Inc. announced that it has established the framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the immunoglobulin therapy Yimmugo® in the U.S., following its Biologic License Application approval by the U.S. Food and Drug Administration on June 13, 2024.
July 1, 2024
·
5 min read
Policy
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
Grifols announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration for Yimmugo®, an innovative intravenous immunoglobulin therapeutic, to treat primary immunodeficiencies.
June 17, 2024
·
7 min read
Press Releases
Kedrion and Biotest complete long-term Exclusive Distribution Agreement for Yimmugo® in the US
October 2, 2024
·
5 min read
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
Grifols, one of the world’s leading producers of plasma-derived medicines, announced that Biotest, a Grifols Group company, forecasts approximately USD 1 billion in revenue from sales in the United States of its intravenous immunoglobulin Yimmugo® during the next seven years, following recent Food and Drug Administration approval to treat primary immunodeficiencies.
July 1, 2024
·
7 min read
Press Releases
Additional Member for the Board of Directors of Bachem Holding AG
April 3, 2025
·
3 min read
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
April 2, 2025
·
10 min read
Press Releases
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
April 1, 2025
·
4 min read
Press Releases
Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
March 4, 2025
·
5 min read
1 of 39,686
Next